Edmund Bartlett
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (13)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
PURPOSE Several histologic subvariants of retroperitoneal well-differentiated liposarcoma (WDLS) have been described, but their associations with clinical outcomes, underlying genomic differences, and transformation to dedifferentiated liposarcoma (DDLS) are not well-defined. METHODS We identified 276 patients with primary retroperitoneal WDLS and 353 patients with primary retroperitoneal DDLS who underwent resection between July 1982 and July 2021 at our institution. WDLS histology was reviewed by a sarcoma pathologist and divided into three subvariants: lipoma-like, sclerosing/myxoid, or incipient/early dedifferentiated WDLS. We also performed an exploratory genomic analysis on a subset of 140 patients with available next-generation targeted sequencing data generated using the MSK-IMPACT platform. RESULTS Compared with the lipoma-like subvariant, the sclerosing/myxoid (hazard ratio [HR], 3.2) and incipient/early dedifferentiated subvariants (HR, 5.3) and DDLS (HR, 9.6) were independently associated with higher incidence of disease-specific death after controlling for other prognostic factors such as tumor size and resection margins. Both the sclerosing/myxoid (HR, 2.9) and incipient/early dedifferentiated (HR, 5.4) subvariants were also associated with a higher incidence of subsequent dedifferentiation compared with the lipoma-like subvariant. On genomic exploratory analysis, compared with the lipoma-like samples, the sclerosing/myxoid and incipient/early dedifferentiated samples had significantly higher copy number log ratios (CNLRs) of MDM2 and CDK4 , with the incipient/early dedifferentiated samples having similar CNLRs of MDM2 and CDK4 to DDLS samples. CONCLUSION WDLS subvariants exhibit both a morphological and genomic progression along the WDLS to DDLS disease spectrum. Distinguishing between them is clinically meaningful for accurate patient counseling and enrollment and stratification in future clinical trials.
Year:
2025
Background Metastasectomy is a useful adjunct in the management of metastatic cancer. Widespread adoption of novel targeted and immunotherapies has improved the survival profiles of multiple malignancies, which has potentially altered the role of metastasectomy. This study aimed to characterize trends in metastasectomy across five primary cancers eligible for these therapies. Methods The National Inpatient Sample was used to identify patients who underwent metastasectomy in the United States (2016–2021). Patients with procedure codes for resection of the lung, liver, adrenal gland, brain, or small bowel and concurrent diagnosis codes for secondary malignant neoplasm of that site were included. Subjects were subcategorized by primary malignancy: colorectal cancer, lung cancer, breast cancer, melanoma, or renal cancer. Sample weights were used to produce national estimates, which were incidence adjusted by primary malignancy. Trends in utilization were calculated with average annual percent change (AAPC) and linear regression coefficients. Results Colorectal cancer was the most frequent indication for metastasectomy ( n = 57,644 cases), followed by lung cancer ( n = 55,090 cases), breast cancer ( n = 12,616 cases), renal cancer ( n = 8427 cases), and melanoma ( n = 5658 cases). Utilization of metastasectomy increased over the study period for breast cancer (AAPC, +10.6%; p = .013) and melanoma (AAPC, +8.3%; p = .040) but did not change for lung cancer (AAPC, −1.6%; p = .26), colorectal cancer (AAPC, +0.3%; p = .83), or renal cancer (AAPC, +2.3%; p = .36). Conclusions Between 2016 and 2021, utilization of metastasectomy increased significantly for melanoma and breast cancer. The role of metastasectomy will likely continue to develop as new treatment protocols improve survival profiles for patients with metastatic disease.
Year:
2025
Purpose: This study investigated factors that affected ctDNA detection and ctDNA as a molecular biomarker in a phase II trial of imatinib and binimetinib in newly diagnosed advanced gastrointestinal stromal tumor, including patients exposed to imatinib within 4 weeks of trial enrollment. Experimental Design: Plasma and tumor tissue samples were collected at baseline, during treatment, and upon progression. DNAs extracted from plasma and tumor tissue were analyzed using genomic assays, Memorial Sloan Kettering Analysis of Circulating cfDNA to Evaluate Somatic Status and Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets, respectively. Sequenced ctDNA detection of the primary oncogenic driver was determined and correlated with clinical characteristics. Results: Patients ( n = 31) included in this analysis had KIT mutations ( n = 29, 94%) and metastatic disease ( n = 24, 77%) and achieved the best response of partial response ( n = 22, 71%), stable disease ( n = 8, 26%), or progressive disease ( n = 1, 3%). Sixteen patients (52%) were exposed to imatinib at baseline. The ctDNA detection rate of the primary oncogenic driver at baseline was 39% ( n = 12/31) and was significantly more likely in patients who were treatment-naïve ( n = 15) or had ≤4.2 weeks of treatment ( n = 8) than in those otherwise (48% vs. 13%; P value = 0.004). Baseline ctDNA detection did not correlate with tumor burden or stage. The ctDNA serial analysis of the primary oncogenic driver paralleled and sometimes preceded radiographic response. ctDNA detected resistance mutations in KIT ( n = 4). Active treatment influenced the detection of secondary KIT alterations in one patient. Conclusions: Active therapy at the time of ctDNA collection negatively affected the ability to detect primary and secondary KIT alterations in sequenced ctDNA from patients with advanced gastrointestinal stromal tumor. ctDNA responses may precede radiographic responses and merit further investigation.
Year:
2025
Purpose: Epacadostat, an indole 2,3 dioxygenase 1 (IDO1) inhibitor, proposed to shift the tumor microenvironment toward an immune-stimulated state, showed early promise in melanoma but has not been studied in sarcoma. This study combined epacadostat with pembrolizumab, which has modest activity in select sarcoma subtypes. Patients and Methods: This phase II study enrolled patients with advanced sarcoma into five cohorts including (i) undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma, (ii) liposarcoma (LPS), (iii) leiomyosarcoma (LMS), (iv) vascular sarcoma, including angiosarcoma and epithelioid hemangioendothelioma (EHE), and (v) other subtypes. Patients received epacadostat 100 mg twice daily plus pembrolizumab at 200 mg/dose every 3 weeks. The primary endpoint was best objective response rate (ORR), defined as complete response (CR) and partial response (PR), at 24 weeks by RECIST v.1.1. Results: Thirty patients were enrolled [60% male; median age 54 years (range, 24–78)]. The best ORR at 24 weeks was 3.3% [PR, n = 1 (leiomyosarcoma); two-sided 95% CI, 0.1%–17.2%]. The median PFS was 7.6 weeks (two-sided 95% CI, 6.9–26.7). Treatment was well tolerated. Grade 3 treatment-related adverse events occurred in 23% ( n = 7) of patients. In paired pre- and post-treatment tumor samples, no association was found between treatment and PD-L1 or IDO1 tumor expression or IDO-pathway–related gene expression by RNA sequencing. No significant changes in serum tryptophan or kynurenine levels were observed after baseline. Conclusions: Combination epacadostat and pembrolizumab was well tolerated and showed limited antitumor activity in sarcoma. Correlative analyses suggested that inadequate IDO1 inhibition was achieved.
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Collaborators (9)
Mark A. Dickson
-
Michael Charles Lowe
Emory University
Samuel Singer
Vincent Astor Chair of Clinical Research
Memorial Sloan Kettering Cancer Center
Sam S. Yoon
-
Benjamin A Nacev
University of Pittsburgh
Robert G. Maki
Professor, Member
-
Jason Chan
Cedars-Sinai Medical Center
Ciara Kelly
-
Georgia Beasley
Associate Professor
Duke University School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.